CAN FITE BIOPHARMA reports positive data from Phase-II study of
CAN FITE BIOPHARMA (NYSE:CANF) proliferated 11.24% since last week. The company, on June 30 announced its final data analysis of the NASH study, which is in Phase-II. The company announced that it observed positive data, where there was sustained reduction and highly efficient too, in the volume of fat liver, across the study duration.
The company is conducting this study for the drug, namodenoson which is showing continuous safety profile. Namodenoson is the oral small molecule drug, which is generically called Cl-IB-MECA. The results from company’s study show that 25 mg of the drug shows considerably efficiency and safety and is seen as the optimal dose, depending upon liver enzymes and MRI-PDFF analysis.
The company is conducting this study for the drug, namodenoson which is showing continuous safety profile. Namodenoson is the oral small molecule drug, which is generically called Cl-IB-MECA. The results from company’s study show that 25 mg of the drug shows considerably efficiency and safety and is seen as the optimal dose, depending upon liver enzymes and MRI-PDFF analysis.
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.